Cargando…
Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group
BACKGROUND: Historically, a priori power and sample size calculations have not been routinely performed cost-effectiveness analyses (CEA), partly because the absence of published cost and effectiveness correlation and variance data, which are essential for power and sample size calculations. Importa...
Autores principales: | Everest, Louis, Chen, Bingshu E., Hay, Annette E., Cheung, Matthew C., Chan, Kelvin K. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398980/ https://www.ncbi.nlm.nih.gov/pubmed/37537545 http://dx.doi.org/10.1186/s12874-023-01956-y |
Ejemplares similares
-
Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials
por: Cheung, Matthew C, et al.
Publicado: (2021) -
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
por: Hoch, Jeffrey S., et al.
Publicado: (2019) -
PGA: power calculator for case-control genetic association analyses
por: Menashe, Idan, et al.
Publicado: (2008) -
The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group
por: Chan, Kelvin K. W., et al.
Publicado: (2021) -
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
por: Hay, Annette E, et al.
Publicado: (2021)